405230-97-9

Usage

Explanation

The molecular formula represents the number of atoms of each element present in a molecule. In this case, the compound has 8 carbon (C), 5 hydrogen (H), 1 chlorine (Cl), 1 fluorine (F), and 2 nitrogen (N) atoms.

Explanation

Pyridine is a heterocyclic aromatic organic compound with a six-membered nitrogen-containing ring. The compound belongs to this class due to the presence of the pyridine ring in its structure.

Explanation

Imidazopyridine is a fused ring system consisting of an imidazole and a pyridine ring. The compound is a derivative of imidazopyridine, meaning it is structurally related and has a similar core structure.

Explanation

The compound has a chlorine atom substituted at the 4th position on the imidazopyridine ring, which is an important feature for its chemical properties and potential applications.

Explanation

The compound also has a fluorine atom substituted at the 7th position on the imidazopyridine ring, which can influence its reactivity, stability, and biological activity.

Explanation

Due to its unique structure and functional groups, the compound can be used as a starting material or intermediate in the synthesis of various biologically active compounds, which can have therapeutic applications.

Explanation

The 9CI (Chemical Abstracts Index Name) is a systematic name assigned to a specific chemical compound, which helps in identifying and distinguishing it from other similar compounds.

Chemical Class

Pyridine

Derivative

Imidazopyridine

Chlorine Substitution

4th position

Fluorine Substitution

7th position

Pharmaceutical Industry Application

Potential building block for synthesis of biologically active compounds

Medicinal Chemistry and Drug Discovery Research

Potential applications

9CI

9CI is a unique identifier assigned to the compound by the Chemical Abstracts Service (CAS) registry.

Upstream product

• 122-51-0 orthoformic acid triethyl ester 
• 405230-93-5 2-chloro-3,4-diamino-5-fluoropyridine 
• 405230-90-2 4-amino-2-chloro-5-fluoro-3-nitropyridine 
• 405230-80-0 2-chloro-5-fluoro-4-nitropyridine-1-oxide 
• 405230-86-6 2-chloro-5-fluoro-4-nitraminopyridine 
• 89510-90-7 4-amino-2-chloro-5-fluoropyridine 
• 405230-79-7 2-chloro-5-fluoropyridine-1-oxide 
• 31301-51-6 2-chloro-5-fluoropyridine 
• 405231-23-4 1-[(1-acetyloxy-1-ethoxy)methyl]-4-chloro-7-fluoroimidazo[4,5-c]pyridine 
• 14036-06-7 diethoxymethyl acetate 

Downstream Products

• 202806-40-4 3-deaza-3-fluoro-adenosine 
• 866554-26-9 C₃₃H₂₅ClFN₃O₇ 
• 405231-08-5 4-chloro-7-fluoro-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)imidazo[4,5-c]pyridine 

Relevant academic research and scientific papers

TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed.

Novel nucleosides and related processes, pharmaceutical compositions and methods

The invention provides novel nucleosides and related processes, pharmaceutical compositions, and methods. The novel nucleosides are useful in a wide variety of antiviral, antineoplastic, and antibacterial applications. Preferred embodiments of the instant invention include novel 2 halogen-substituted, 3 halogen-substituted, and 2′,3′dihalogen-substituted analogues of 3-deazaadenosine, and novel 3 halogen-substituted analogues of 3-deazaguanosine. Compounds of the instant invention, including 4-Amino-6-fluoro-1-(β-D-ribofuranosyl)imidazo[4,5-c]pyridine and 6-Amino-7-bromo-1,5-dihydro-1-β-D-ribofuranosylimidazo[4,5-c]pyridin-4-one, have exhibited potent antiviral and anticancer activity in vitro. The compounds are also useful in the concomitant treatment of bacterial infections associated with viral infections such as AIDS.

Synthesis of halogen-substituted 3-deazaadenosine and 3-deazaguanosine analogues as potential antitumor/antiviral agents

Various 2-halogen-substituted analogues (38, 39, 43 and 44), 3-halogensubstituted analogues (51 and 52), and 2′,3′ -dihalogen- substituted analogues (57-60) of 3-deazaadenosine and 3-halogen-substituted analogues (61 and 62) of 3-deazaguanosine have been synthesized as potential anticancer and/or antiviral agents. Among these compounds, 3-deaza-3-bromoguanosine (62) showed significant cytotoxicity against L1210, P388, CCRF-CEM and B16F10 cell lines in vitro, producing IC50 values of 3, 7, 9 and 7μM, respectively. Several 3-deazaadenosine analogues (38, 51, 57 and 59) showed moderate to weak activity against hepatitis B virus.